Compare e l f Beauty Inc (ELF) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
e l f Beauty Inc vs Organon & Co. Common Stock — how do they compare? e l f Beauty Inc trades at $107.01 (market cap $6.38B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: e l f Beauty Inc is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while e l f Beauty Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold e l f Beauty Inc for 26 Days and Organon & Co. Common Stock for 0 Days on average.
| ELF | OGN | |
|---|---|---|
Market Cap | $6.38B | $3.62B |
Volume | 856,198 | 2,892,999 |
Sector | Consumer Staples | Health |
52-Week High | $136.92 | $13.81 |
52-Week Low | $49.57 | $5.70 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $6.97B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ELF Beauty trades at $108.16, down 1.62% today, with strong technical momentum showing bullish moving averages but overbought RSI readings. The company demonstrates robust revenue growth with Q2 2026 earnings beating expectations by 145%, though valuation metrics remain elevated with a P/E of 110.37. Recent expansion includes rhode brand launches in 19 European markets via Sephora and innovative marketing campaigns like the 'Mirror Mix' music album.
Outlook remains positive with analyst consensus leaning bullish (48% buy ratings) despite premium valuation. Key opportunities include international expansion and market share gains, while risks center on margin compression and competitive pressures in the beauty sector. The stock trades above consensus price target of $95.91, suggesting near-term consolidation potential.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About e l f Beauty Inc
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
